ASHLEY BURR: Open Payments
NPI 1821510389 · COLUMBIA, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,215 in 43 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $22 · 2025 $1,215
Food & beverage: $1,215
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $354 |
| GENZYME CORPORATION | 6 | $239 |
| Incyte Corporation | 2 | $159 |
| Regeneron Healthcare Solutions, Inc. | 3 | $80 |
| Grifols USA, LLC | 3 | $69 |
| Novartis Pharmaceuticals Corporation | 3 | $54 |
| Genentech USA, Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| SANOFI US SERVICES INC. | 1 | $25 |
Products named: DUPIXENT, FASENRA, AIRSUPRA, Prolastin-C Liquid, Xolair, TEZSPIRE, NUCALA, Rhapsido.
Industry payments across MO — which companies pay providers there.
